Velarion · Company Intelligence
Compensation Brief
Fiscal year 2023 · Filings through 2026-07-22

Allakos (ALLK)

CEO Robert Alexander was paid $6,299,426 in fiscal year 2023, ↓ down 14.5% from fiscal year 2022, the 75th percentile of its disclosed peer group (SEC filing 0000950170-24-047043 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$6,299,426 ↓
Robert Alexander total, FY2023
75th
CEO pay percentile vs peers
—
CEO-to-median pay ratio
85.47%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Robert Alexander (Chief Executive Officer and Director), FY2023 total compensation $6,299,426 (base salary $805,460) [exec_comp, SEC accession 0000950170-24-047043, filed 2024-04-23]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

01

Summary Compensation Table — fiscal year 2023

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Robert Alexander$805,460$0$2,171,340$2,623,519$684,641$0$14,466$6,299,426
Chief Executive Officer and Director
Adam Tomasi709,67001,411,1781,705,059425,802014,4664,266,175
President
Baird Radford494,4000911,8081,101,693222,480014,4662,744,847
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2023 totalFY2022 totalFY2021 totalΔ FY2022→2023
Robert Alexander$6,299,426$7,366,205$10,988,477↓ −1,066,779
Adam Tomasi4,266,1754,954,3707,258,214↓ −688,195
Baird Radford2,744,8473,359,9656,018,813↓ −615,118

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Allakos's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ALLK reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against ALLK
4 companies name ALLK as a compensation peer

Each company listed discloses ALLK in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ALLK in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2023 total
Baird RadfordCFO$2,744,847
Robert AlexanderCEO$6,299,426
Adam TomasiPresident$4,266,175
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2023 total
Amy L. LaddIndependent Director$372,117
Daniel JanneyChair of the Board$434,617
Dolca ThomasIndependent Director$732,475
E. Rand SutherlandIndependent Director$732,475
John McKearnFormer director (through FY2023)$32,500
Neil GrahamIndependent Director$378,275
Paul WalkerIndependent Director$387,117
Robert E. AndreattaIndependent Director$389,617
Steven P. JamesIndependent Director$387,117
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Baird RadfordChief Financial Officer2025-03-05D14,161$0$3,682CommonForm 4 ↗
Adam TomasiPresident2025-03-05D20,01705,204CommonForm 4 ↗
Robert AlexanderDirector2025-03-06D31,37008,156CommonForm 4 ↗
Neil GrahamDirector2025-05-15D154,78600Derivative, Class A CommonForm 4 ↗
Baird RadfordChief Financial Officer2025-05-15D194,14400Derivative, Class A CommonForm 4 ↗
Paul WalkerDirector2025-05-15D41,00000Derivative, Class A CommonForm 4 ↗
Paul WalkerDirector2025-05-15D7,70000Derivative, Class A CommonForm 4 ↗
Paul WalkerDirector2025-05-15D16,00000Derivative, Class A CommonForm 4 ↗
Paul WalkerDirector2025-05-15D3,386,400——Common, indirectForm 4 ↗
BVF PARTNERS L P/ILGreater-than-10% holder2025-05-15D855,211——Common, indirectForm 4 ↗
Robert AlexanderDirector2025-05-15D462,32500Derivative, Class A CommonForm 4 ↗
Robert AlexanderDirector2025-05-15D250,00000Derivative, Class A CommonForm 4 ↗
Robert AlexanderDirector2025-05-15D306,96000Derivative, Class A CommonForm 4 ↗
Robert AlexanderDirector2025-05-15D290,02200Derivative, Class A CommonForm 4 ↗
Robert AlexanderDirector2025-05-15D912,50000Derivative, Class A CommonForm 4 ↗
Robert AlexanderDirector2025-05-15D738,104——CommonForm 4 ↗
Robert E. AndreattaDirector2025-05-15D37,60000Derivative, Class A CommonForm 4 ↗
Neil GrahamDirector2025-05-15D41,00000Derivative, Class A CommonForm 4 ↗
Steven P. JamesDirector2025-05-15D86,76200Derivative, Class A CommonForm 4 ↗
Steven P. JamesDirector2025-05-15D7,70000Derivative, Class A CommonForm 4 ↗
Steven P. JamesDirector2025-05-15D55,38000Derivative, Class A CommonForm 4 ↗
Baird RadfordChief Financial Officer2025-05-15D27,60000Derivative, Class A CommonForm 4 ↗
Baird RadfordChief Financial Officer2025-05-15D163,426——CommonForm 4 ↗
Dolca ThomasDirector2025-05-15D41,00000Derivative, Class A CommonForm 4 ↗
Adam TomasiPresident2025-05-15D125,00000Derivative, Class A CommonForm 4 ↗
Paul WalkerDirector2025-05-15D86,76200Derivative, Class A CommonForm 4 ↗
Paul WalkerDirector2025-05-15D99,59000Derivative, Class A CommonForm 4 ↗
Paul WalkerDirector2025-05-15D7,70000Derivative, Class A CommonForm 4 ↗
Paul WalkerDirector2025-05-15D37,60000Derivative, Class A CommonForm 4 ↗
BVF PARTNERS L P/ILGreater-than-10% holder2025-05-15D6,777,935——Common, indirectForm 4 ↗
BVF PARTNERS L P/ILGreater-than-10% holder2025-05-15D8,679,726——Common, indirectForm 4 ↗
Paul WalkerDirector2025-05-15D2,760,860——Common, indirectForm 4 ↗
Robert AlexanderDirector2025-05-15D2,000,00000Derivative, Class A CommonForm 4 ↗
Steven P. JamesDirector2025-05-15D99,59000Derivative, Class A CommonForm 4 ↗
Steven P. JamesDirector2025-05-15D16,00000Derivative, Class A CommonForm 4 ↗
Steven P. JamesDirector2025-05-15D18,80000Derivative, Class A CommonForm 4 ↗
Steven P. JamesDirector2025-05-15D41,00000Derivative, Class A CommonForm 4 ↗
Steven P. JamesDirector2025-05-15D7,70000Derivative, Class A CommonForm 4 ↗
Dolca ThomasDirector2025-05-15D154,78600Derivative, Class A CommonForm 4 ↗
Amy L. LaddDirector2025-05-15D233,17700Derivative, Class A CommonForm 4 ↗
Amy L. LaddDirector2025-05-15D41,00000Derivative, Class A CommonForm 4 ↗
Amy L. LaddDirector2025-05-15D86,76200Derivative, Class A CommonForm 4 ↗
Robert E. AndreattaDirector2025-05-15D99,59000Derivative, Class A CommonForm 4 ↗
Robert E. AndreattaDirector2025-05-15D7,70000Derivative, Class A CommonForm 4 ↗
Robert E. AndreattaDirector2025-05-15D7,70000Derivative, Class A CommonForm 4 ↗
Robert E. AndreattaDirector2025-05-15D41,00000Derivative, Class A CommonForm 4 ↗
Robert E. AndreattaDirector2025-05-15D86,76200Derivative, Class A CommonForm 4 ↗
Robert E. AndreattaDirector2025-05-15D16,00000Derivative, Class A CommonForm 4 ↗
Robert AlexanderDirector2025-05-15D320,300——CommonForm 4 ↗
Adam TomasiPresident2025-05-15D512,630——CommonForm 4 ↗
Adam TomasiPresident2025-05-15D1,200,00000Derivative, Class A CommonForm 4 ↗
Adam TomasiPresident2025-05-15D300,47100Derivative, Class A CommonForm 4 ↗
Adam TomasiPresident2025-05-15D145,01100Derivative, Class A CommonForm 4 ↗
Adam TomasiPresident2025-05-15D88,03600Derivative, Class A CommonForm 4 ↗
Adam TomasiPresident2025-05-15D486,40000Derivative, Class A CommonForm 4 ↗
Adam TomasiPresident2025-05-15D20,790——CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2023

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Adam TomasiOPTION2023-01-06——300,471—$1,705,059
Robert AlexanderRSU2023-01-06——301,575—2,171,340
Baird RadfordOPTION2023-01-06——194,144—1,101,693
Adam TomasiRSU2023-01-06——195,997—1,411,178
Robert AlexanderOPTION2023-01-06——462,325—2,623,519
Baird RadfordRSU2023-01-06——126,640—911,808
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Adam Tomasi$1,411,178$0$1,705,0590.0%
Robert Alexander2,171,34002,623,5190.0%
Baird Radford911,80801,101,6930.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2023

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Adam TomasiRSU19,625—$53,576
Adam TomasiRSU16,681—45,539
Robert AlexanderRSU297,745—812,844
Adam TomasiRSU193,534—528,348
Adam TomasiRSU195,997—535,072
Baird RadfordRSU133,655—364,878
Robert AlexanderRSU30,400—82,992
Robert AlexanderPSU17,227—47,030
Adam TomasiPSU11,121—30,360
Baird RadfordRSU6,413—17,507
Robert AlexanderOption462,3257.2—
Baird RadfordOption194,1447.2—
Baird RadfordOption9,200105.16—
Baird RadfordRSU126,640—345,727
Robert AlexanderRSU25,841—70,546
Baird RadfordRSU12,128—33,109
Adam TomasiPSU344,060—939,284
Robert AlexanderRSU301,575—823,300
Adam TomasiOption300,4717.2—
Robert AlexanderPSU529,323—1,445,052
Baird RadfordPSU237,608—648,670
05

Incentive-plan design — the Compensation Discussion & Analysis

The guiding principle in the development of our compensation strategy is to create and nurture a pay-for-performance culture, where contributions to enhancing stockholder value have the potential to be matched with appropriate financial rewards.

CEO STI target (% of salary)85%
CEO LTI target (% of salary)—
Independent consultantCompensia
Clawback policyTrue
Anti-hedgingFalse
Anti-pledgingFalse
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20242024-05-2457,581,1869,731,50256,96985.47%Passed
20212021-05-2519,865,65228,179,0124,06341.35%Failed
20192019-06-06—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20242024-05-2485.47%a
20212021-05-2541.35%b
20192019-06-06—c

a. Approved under the standard stated in the filing — “Abstentions will have the same effect as a vote AGAINST this proposal.”.

b. Approved under the standard stated in the filing — “On other matters submitted for a vote, broker 3 Table of Contents non-votes will not be considered in tallying votes cast, and abstentions will be treated as a vote "against." If less than a majority of the combined voting power of the outstanding shares of common stock is represented at the 202 1 Annual Meeting, a majority of the shares so represented may adjourn the 202 1 Annual Meeting from time to time without further notice.”.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2023

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
E. Rand SutherlandIndependent · Research and Clinical Development · Not standing for re-election$18,333$0$714,142—$0$732,475
Dolca ThomasIndependent · Research and Clinical Development18,3330714,142—0732,475
Daniel JanneyIndependent · Board Chair · Compensation · Corporate Governance and Nominating (Chair) · Not standing for re-election112,5000322,117—0434,617
Robert E. AndreattaIndependent · Audit (Chair) · Corporate Governance and Nominating67,5000322,117—0389,617
Paul WalkerIndependent · Audit · Compensation65,0000322,117—0387,117
Steven P. JamesIndependent · Audit · Corporate Governance and Nominating65,0000322,117—0387,117
Neil GrahamIndependent · Research and Clinical Development13,7500364,525—0378,275
Amy L. LaddIndependent · Compensation · Corporate Governance and Nominating50,0000322,117—0372,117
John McKearnIndependent · Departed during FY32,5000——032,500
Robert AlexanderEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer$47,500
Annual equity retainer$296,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2023
Cash retainers and fees$442,916
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$442,916

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2023

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Allakos names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Allakos.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Cogent Biosciences, Inc.2025Andrew Robbins$724,554$12,993,250$13,447,680$561,600$27,762,684
2Immunovant, Inc.2026Eric Venker636,618019,010,639020,158,767
3Kiniksa Pharmaceuticals, Ltd.2025Sanj Patel943,1293,798,0214,743,4461,284,06510,782,661
4Allakos2023Robert Alexander805,4602,171,3402,623,519684,6416,299,426
5Allogene Therapeutics, Inc.2025David Chang724,0002,409,5372,588,329400,0106,136,093
6AnaptysBio, Inc.2025Daniel Faga706,0111,592,0013,345,653465,9686,133,943
7Celldex Therapeutics, Inc.2025Anthony Marucci785,80404,027,59005,366,709
8Omeros Corporation2025Gregory Demopulos972,52502,207,97404,178,008
9Annexon, Inc.2025Douglas Love670,83302,522,260371,2503,579,202
10Fulcrum Therapeutics, Inc.2025Alex Sapir650,00002,052,132411,2003,251,490
11Kodiak Sciences Inc.2025Victor Perlroth792,4970923,032772,8242,499,221
12Alector, Inc.2025Arnon Rosenthal678,100422,876558,216325,4881,995,018
13PMV Pharmaceuticals, Inc.2025David Mack628,4610752,320284,4101,665,191
14Mersana Therapeutics, Inc.2024Michael Huber632,500133,635518,044322,5751,613,754
—Outlook Therapeutics, Inc.——————not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Allakosnot disclosedOptions 55 · RSU 45NoCompensia
Alector, Inc.80%not disclosednot disclosedPearl Meyer & Partners, LLC
Allogene Therapeutics, Inc.not disclosedOption 55 · RSU 25 · PSU 20not disclosedCompensia
AnaptysBio, Inc.110%not disclosedNoAlpine Rewards
Annexon, Inc.100% of target%not disclosednot disclosedAlpine Rewards
Celldex Therapeutics, Inc.100%Options 100not disclosedAon (Human Capital Solutions practice, a division of Aon plc)
Cogent Biosciences, Inc.135%not disclosedNoCompensia
Fulcrum Therapeutics, Inc.not disclosedOption 100not disclosedAon
Immunovant, Inc.110%not disclosedNoCompensia
Kiniksa Pharmaceuticals, Ltd.not disclosedOption 50 · RSU 25 · PSU 25not disclosedCompensia, Inc.
Kodiak Sciences Inc.150%Options 100not disclosedCompensia, Inc.
Mersana Therapeutics, Inc.not disclosedOption 75 · RSU 25not disclosedPearl Meyer & Partners, LLC
Omeros Corporationnot disclosedOption 100not disclosedCompensia
Outlook Therapeutics, Inc.not disclosednot disclosednot disclosednot disclosed
PMV Pharmaceuticals, Inc.not disclosedOption 100not disclosedPearl Meyer & Partners, LLC

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Allakos in fiscal 2023?
As disclosed, Robert Alexander (Chief Executive Officer and Director) was the highest-paid executive at Allakos in fiscal 2023, with total compensation of $6,299,426.
How does Allakos's chief executive pay compare to its disclosed peer group?
As disclosed, Robert Alexander's total compensation ranked at the 75th percentile of Allakos's disclosed peer group.
How did shareholders vote on Allakos's executive compensation?
As disclosed, 85.47% of shareholders supported Allakos's executive compensation in the latest say-on-pay vote.
How much does Allakos spend in total on board compensation for fiscal 2023?
As disclosed, Allakos reported total board compensation of $442,916 for fiscal 2023.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Robert AlexanderDEF 14A2024-04-230000950170-24-047043Section “Summary Compensation Table for Fiscal Year 2023”. As printed: 6,299,426. Filing ↗machine: r2 · c26 · span 505098–505107
2Section 01, Adam TomasiDEF 14A2024-04-230000950170-24-047043Section “Summary Compensation Table for Fiscal Year 2023”. As printed: 4,266,175. Filing ↗machine: r8 · c26 · span 546255–546264
3Section 01, Baird RadfordDEF 14A2024-04-230000950170-24-047043Section “Summary Compensation Table for Fiscal Year 2023”. As printed: 2,744,847. Filing ↗machine: r5 · c26 · span 525677–525686
4Section 03, Adam Tomasi OPTIONDEF 14A2024-04-230000950170-24-047043Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r10 · c25 · span 633943–633952
5Section 03, Robert Alexander RSUDEF 14A2024-04-230000950170-24-047043Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r3 · c24 · span 585655–585664
6Section 03, Baird Radford OPTIONDEF 14A2024-04-230000950170-24-047043Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r7 · c25 · span 613559–613568
7Section 03, Adam Tomasi RSUDEF 14A2024-04-230000950170-24-047043Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r9 · c24 · span 627093–627102
8Section 03, Robert Alexander OPTIONDEF 14A2024-04-230000950170-24-047043Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r4 · c25 · span 592508–592517
9Section 03, Baird Radford RSUDEF 14A2024-04-230000950170-24-047043Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t16 · r6 · c24 · span 606486–606493
10Section 08, E. Rand SutherlandDEF 14A2024-04-230000950170-24-047043Section “Director Compensation”. As printed: 732,475. Filing ↗machine: t25 · r7 · c11 · span 1144111–1144302
11Section 08, Dolca ThomasDEF 14A2024-04-230000950170-24-047043Section “Director Compensation”. As printed: 732,475. Filing ↗machine: t25 · r8 · c11 · span 1147376–1147567
12Section 08, Daniel JanneyDEF 14A2024-04-230000950170-24-047043Section “Director Compensation”. As printed: 434,617. Filing ↗machine: t25 · r2 · c11 · span 1127806–1127997
13Section 08, Robert E. AndreattaDEF 14A2024-04-230000950170-24-047043Section “Director Compensation”. As printed: 389,617. Filing ↗machine: t25 · r3 · c11 · span 1131068–1131259
14Section 08, Paul WalkerDEF 14A2024-04-230000950170-24-047043Section “Director Compensation”. As printed: 387,117. Filing ↗machine: t25 · r4 · c11 · span 1134322–1134513
15Section 08, Steven P. JamesDEF 14A2024-04-230000950170-24-047043Section “Director Compensation”. As printed: 387,117. Filing ↗machine: t25 · r5 · c11 · span 1137580–1137771
16Section 08, Neil GrahamDEF 14A2024-04-230000950170-24-047043Section “Director Compensation”. As printed: 378,275. Filing ↗machine: t25 · r9 · c11 · span 1150640–1150831
17Section 08, Amy L. LaddDEF 14A2024-04-230000950170-24-047043Section “Director Compensation”. As printed: 372,117. Filing ↗machine: t25 · r6 · c11 · span 1140840–1141031
18Section 08, John McKearnDEF 14A2024-04-230000950170-24-047043Section “Director Compensation”. As printed: 32,500. Filing ↗machine: t25 · r10 · c3 · span 1151967–1152157
19Section 08, Robert AlexanderDEF 14A2024-04-230000950170-24-047043Section “Director Compensation”. As printed: 0. Filing ↗
20Section 02, Baird Radford 2025-03-05Form 42025-03-070000950170-25-035648Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Adam Tomasi 2025-03-05Form 42025-03-070000950170-25-035653Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Robert Alexander 2025-03-06Form 42025-03-070000950170-25-035650Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Neil Graham 2025-05-15Form 42025-05-150001104659-25-049387Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Baird Radford 2025-05-15Form 42025-05-150001104659-25-049408Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Paul Walker 2025-05-15Form 42025-05-150000950170-25-072714Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Paul Walker 2025-05-15Form 42025-05-150000950170-25-072714Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Paul Walker 2025-05-15Form 42025-05-150000950170-25-072714Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Paul Walker 2025-05-15Form 42025-05-150000950170-25-072714Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, BVF PARTNERS L P/IL 2025-05-15Form 42025-05-190000921895-25-001590Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Robert Alexander 2025-05-15Form 42025-05-150001104659-25-049368Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Robert Alexander 2025-05-15Form 42025-05-150001104659-25-049368Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Robert Alexander 2025-05-15Form 42025-05-150001104659-25-049368Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Robert Alexander 2025-05-15Form 42025-05-150001104659-25-049368Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Robert Alexander 2025-05-15Form 42025-05-150001104659-25-049368Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Robert Alexander 2025-05-15Form 42025-05-150001104659-25-049368Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Robert E. Andreatta 2025-05-15Form 42025-05-150001104659-25-049379Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Neil Graham 2025-05-15Form 42025-05-150001104659-25-049387Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Steven P. James 2025-05-15Form 42025-05-150001104659-25-049394Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Steven P. James 2025-05-15Form 42025-05-150001104659-25-049394Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Steven P. James 2025-05-15Form 42025-05-150001104659-25-049394Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Baird Radford 2025-05-15Form 42025-05-150001104659-25-049408Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Baird Radford 2025-05-15Form 42025-05-150001104659-25-049408Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Dolca Thomas 2025-05-15Form 42025-05-150001104659-25-049419Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Adam Tomasi 2025-05-15Form 42025-05-150001104659-25-049427Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Paul Walker 2025-05-15Form 42025-05-150000950170-25-072714Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Paul Walker 2025-05-15Form 42025-05-150000950170-25-072714Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Paul Walker 2025-05-15Form 42025-05-150000950170-25-072714Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Paul Walker 2025-05-15Form 42025-05-150000950170-25-072714Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, BVF PARTNERS L P/IL 2025-05-15Form 42025-05-190000921895-25-001590Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, BVF PARTNERS L P/IL 2025-05-15Form 42025-05-190000921895-25-001590Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Paul Walker 2025-05-15Form 42025-05-150000950170-25-072714Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Robert Alexander 2025-05-15Form 42025-05-150001104659-25-049368Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Steven P. James 2025-05-15Form 42025-05-150001104659-25-049394Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Steven P. James 2025-05-15Form 42025-05-150001104659-25-049394Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Steven P. James 2025-05-15Form 42025-05-150001104659-25-049394Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Steven P. James 2025-05-15Form 42025-05-150001104659-25-049394Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Steven P. James 2025-05-15Form 42025-05-150001104659-25-049394Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Dolca Thomas 2025-05-15Form 42025-05-150001104659-25-049419Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Amy L. Ladd 2025-05-15Form 42025-05-150001104659-25-049398Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Amy L. Ladd 2025-05-15Form 42025-05-150001104659-25-049398Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Amy L. Ladd 2025-05-15Form 42025-05-150001104659-25-049398Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Robert E. Andreatta 2025-05-15Form 42025-05-150001104659-25-049379Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Robert E. Andreatta 2025-05-15Form 42025-05-150001104659-25-049379Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Robert E. Andreatta 2025-05-15Form 42025-05-150001104659-25-049379Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Robert E. Andreatta 2025-05-15Form 42025-05-150001104659-25-049379Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Robert E. Andreatta 2025-05-15Form 42025-05-150001104659-25-049379Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Robert E. Andreatta 2025-05-15Form 42025-05-150001104659-25-049379Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Robert Alexander 2025-05-15Form 42025-05-150001104659-25-049368Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Adam Tomasi 2025-05-15Form 42025-05-150001104659-25-049427Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Adam Tomasi 2025-05-15Form 42025-05-150001104659-25-049427Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Adam Tomasi 2025-05-15Form 42025-05-150001104659-25-049427Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Adam Tomasi 2025-05-15Form 42025-05-150001104659-25-049427Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Adam Tomasi 2025-05-15Form 42025-05-150001104659-25-049427Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Adam Tomasi 2025-05-15Form 42025-05-150001104659-25-049427Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Adam Tomasi 2025-05-15Form 42025-05-150001104659-25-049427Insider equity transaction reported since the proxy statement. Filing ↗
76Section 06, 2024 voteForm 8-K2024-05-280000950170-24-064883Item 5.07 · say-on-pay result. As reported: 85.47% (votes for as printed: 57,581,186). Filing ↗
77Section 06, 2021 voteForm 8-K2021-05-260001564590-21-030016Item 5.07 · say-on-pay result. As reported: 41.35% (votes for as printed: 19,865,652). Filing ↗
78Section 06, 2019 voteForm 8-K2019-06-100000950123-19-005949Item 5.07 · say-on-pay result. As reported: —. Filing ↗
79Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
80Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
81Section 09b board cost (computed)Computed——Cash 442,916 + equity 0 + all other 0 = 442,916, summed across the director compensation table rows.machine: formula: Σ = 442,916
82Cogent Biosciences, Inc., Section 10b CEO totalDEF 14A2026-04-230001193125-26-173834CEO total compensation as printed in Cogent Biosciences, Inc.'s own proxy. As printed: 27,762,684. Filing ↗machine: r2 · c39 · span 369353–369363
83Immunovant, Inc., Section 10b CEO totalDEF 14A2026-07-220001764013-26-000092CEO total compensation as printed in Immunovant, Inc.'s own proxy. As printed: 20,158,767. Filing ↗machine: span 465716–465726
84Kiniksa Pharmaceuticals, Ltd., Section 10b CEO totalDEF 14A2026-04-160001104659-26-044410CEO total compensation as printed in Kiniksa Pharmaceuticals, Ltd.'s own proxy. As printed: 10,782,661. Filing ↗
85Allakos (subject), Section 10b CEO totalDEF 14A2024-04-230000950170-24-047043CEO total compensation as printed in Allakos's own proxy. As printed: 6,299,426. Filing ↗machine: r2 · c26 · span 505098–505107
86Allogene Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-300001628280-26-028948CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. Filing ↗machine: r2 · c54 · span 451014–451023
87AnaptysBio, Inc., Section 10b CEO totalDEF 14A2026-06-290001193125-26-288408CEO total compensation as printed in AnaptysBio, Inc.'s own proxy. As printed: 6,133,943. Filing ↗machine: span 694406–694415
88Celldex Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-290001104659-26-050884CEO total compensation as printed in Celldex Therapeutics, Inc.'s own proxy. As printed: 5,366,709. Filing ↗machine: r1 · c54 · span 1024857–1024866
89Omeros Corporation, Section 10b CEO totalDEF 14A2026-04-300001552781-26-000281CEO total compensation as printed in Omeros Corporation's own proxy. As printed: 4,178,008. Filing ↗
90Annexon, Inc., Section 10b CEO totalDEF 14A2026-04-270001140361-26-017085CEO total compensation as printed in Annexon, Inc.'s own proxy. As printed: 3,579,202. Filing ↗machine: r2 · c24 · span 356205–356214
91Fulcrum Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-300001193125-26-197196CEO total compensation as printed in Fulcrum Therapeutics, Inc.'s own proxy. As printed: 3,251,490. Filing ↗machine: r2 · c25 · span 336588–336597
92Kodiak Sciences Inc., Section 10b CEO totalDEF 14A2026-04-220001193125-26-170429CEO total compensation as printed in Kodiak Sciences Inc.'s own proxy. As printed: 2,499,221. Filing ↗machine: r4 · c14 · span 905058–905068
93Alector, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-186928CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674
94PMV Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-220001140361-26-016038CEO total compensation as printed in PMV Pharmaceuticals, Inc.'s own proxy. As printed: 1,665,191. Filing ↗machine: r2 · c27 · span 469868–469877
95Mersana Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-290001104659-25-040448CEO total compensation as printed in Mersana Therapeutics, Inc.'s own proxy. As printed: 1,613,754. Filing ↗machine: r1 · c41 · span 608188–608197
96Section 10a, Alector, Inc. reciprocityDEF 14A—0001193125-26-186928Alector, Inc.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗
97Section 10a, Mersana Therapeutics, Inc. reciprocityDEF 14A—0001104659-25-040448Mersana Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗
98Section 10a, Allogene Therapeutics, Inc. reciprocityDEF 14A—0001628280-26-028948Allogene Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗
99Section 10a, Cogent Biosciences, Inc. reciprocityDEF 14A—0001193125-26-173834Cogent Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗
100Section 10a, Immunovant, Inc. reciprocityDEF 14A—0001764013-26-000092Immunovant, Inc.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗
101Section 10a, AnaptysBio, Inc. reciprocityDEF 14A—0001193125-26-288408AnaptysBio, Inc.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗
102Section 10a, Celldex Therapeutics, Inc. reciprocityDEF 14A—0001104659-26-050884Celldex Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗
103Section 10a, Kiniksa Pharmaceuticals, Ltd. reciprocityDEF 14A—0001104659-26-044410Kiniksa Pharmaceuticals, Ltd.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗
104Section 10a, Kodiak Sciences Inc. reciprocityDEF 14A—0001193125-26-170429Kodiak Sciences Inc.'s most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗
105Section 10a, Omeros Corporation reciprocityDEF 14A—0001552781-26-000281Omeros Corporation's most recent proxy was read; its disclosed peer group does not include Allakos. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.